Study finds that resistant cells become vulnerable to MD Anderson-developed targeted therapy HOUSTON ― Researchers at The University of Texas MD Anderson Cancer Centerhave discovered that triple negative breast cancer (TNBC) cells can develop resistance to frontline, or neoadjuvant, chemotherapy not by acquiring permanent adaptations, but rather transiently turning on molecular pathways that protect the cells. The study, published today in Science Translational Medicine, also identifies a vulnerability that may provide a new treatment option for resistant TNBC. Among those pathways […]
